Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CLEVIPREX vs ADALAT CC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cleviprex (clevidipine) is a dihydropyridine L-type calcium channel blocker with high vascular selectivity. It inhibits calcium influx into vascular smooth muscle cells, causing arterial vasodilation and reduced peripheral vascular resistance.
Nifedipine, a dihydropyridine calcium channel blocker, inhibits calcium ion influx across cardiac and smooth muscle cell membranes, leading to vasodilation and decreased myocardial contractility.
For the reduction of blood pressure when oral therapy is not feasible or desirable,For the management of perioperative hypertension
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
Initiate intravenous infusion at 1-2 mg/kg/hr, titrate by 0.5-1 mg/kg/hr every 90 minutes up to maximum 32 mg/kg/hr. Maintenance dose: 4-6 mg/kg/hr. Route: IV. Frequency: continuous infusion.
30 mg orally once daily; may titrate to 60 mg or 90 mg once daily based on response and tolerability.
Terminal elimination half-life: 2.7 minutes (dihydropyridine ring reduction) and 15 minutes (ester hydrolysis); clinical context: rapid offset allows precise titration
Terminal elimination half-life: 7-10 hours; clinical context: sustained-release formulation provides therapeutic concentrations over 24 hours with once-daily dosing, but half-life does not directly reflect drug effect duration due to slow absorption.
Rapidly metabolized by esterases in the blood and extravascular tissues to an inactive carboxylic acid metabolite (H152/81). Not primarily dependent on hepatic CYP450 enzymes.
Hepatic metabolism via CYP3A4; nifedipine is converted to inactive metabolites.
Renal: 63–73% as metabolites, fecal: 7–10%, unchanged drug in urine: <1%
Renal: 70-80% as metabolites, fecal: 15-20% as metabolites, biliary: minimal (<5% unchanged).
87–97% bound to plasma proteins (primarily albumin)
92-98% bound primarily to albumin.
0.32 L/kg (approx. 22 L for 70 kg); indicates limited extravascular distribution
1.2-1.6 L/kg; clinical meaning: indicates extensive tissue distribution, with higher concentrations in organs such as liver and kidney, and lower in brain due to P-glycoprotein efflux.
Intravenous: 100% (only route administered)
65-90% after oral administration; absolute bioavailability of nifedipine in ADALAT CC: approximately 65% due to first-pass metabolism in liver and gut wall.
No dose adjustment required for renal impairment. Clevidipine is not removed by dialysis.
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (Cr Cl <30 m L/min), start at 30 mg once daily and titrate cautiously.
Contraindicated in patients with severe hepatic impairment (Child-Pugh Class C). Use with caution in moderate impairment (Child-Pugh B); consider lower initial doses and titrate slowly.
For mild to moderate hepatic impairment (Child-Pugh A or B), reduce initial dose to 30 mg once daily; for severe impairment (Child-Pugh C), contraindicated or use with extreme caution.
Safety and efficacy not established in pediatric patients. No FDA-approved dosing recommendations.
Safety and efficacy not established; use is not recommended in pediatric patients.
No specific dose adjustment required. Elderly patients may be more sensitive to hypotensive effects; use lower initial doses and titrate cautiously.
Initiate at 30 mg once daily; titrate slowly due to increased risk of hypotension and higher drug exposure. Monitor closely.
None.
No FDA black box warning.
Use caution in patients with heart failure, as beta-blocker withdrawal may exacerbate angina; continue beta-blocker therapy.,Hypotension and reflex tachycardia may occur; monitor blood pressure and heart rate closely.,Can cause acute kidney injury or worsening of renal function in at-risk patients.,Lipid emulsion formulation; use caution in patients with severe hypertriglyceridemia or lipid metabolism disorders.,Contains soybean oil and egg lecithin; contraindicated in patients with allergies to soybeans or eggs.,Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Beta-blocker withdrawal: taper if discontinuing; exacerbation of angina,Heart failure: use caution in patients with severe left ventricular dysfunction,Hepatic impairment: reduce dose,Peripheral edema: may occur; differentiate from worsening heart failure,Monitor blood pressure during initiation and titration
Hypersensitivity to clevidipine or any component of the formulation (including soybean oil or egg lecithin),Severe aortic stenosis (may reduce cardiac output and worsen symptoms),Patients with defective lipid metabolism (e.g., hyperlipoproteinemia, lipoid nephrosis, acute pancreatitis with hyperlipidemia)
Hypersensitivity to nifedipine or any component,Cardiogenic shock,Concurrent use with strong CYP3A4 inducers (e.g., rifampin)
No specific food interactions; administer IV only. The lipid emulsion contains soybean oil and egg lecithin; contraindicated in patients with allergies to soy or eggs. No oral intake required.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, raising nifedipine levels and risk of toxicity. High-fat meals may increase absorption; take consistently with respect to meals. Avoid alcohol as it may exacerbate hypotension.
Cleviprex (clevidipine) is a calcium channel blocker. No adequate and well-controlled studies in pregnant women. In animal studies, no teratogenic effects were observed at clinically relevant doses. However, maternal toxicity at high doses led to fetal effects (reduced fetal weight, delayed ossification). First trimester: limited data; risk cannot be excluded. Second and third trimesters: may cause fetal acidosis, hypotension, and bradycardia due to maternal hypotension. Use only if potential benefit justifies potential risk.
Adalat CC (nifedipine) is an extended-release formulation of nifedipine, a dihydropyridine calcium channel blocker. In animal studies, nifedipine has been associated with embryotoxicity, fetotoxicity, and teratogenicity (e.g., digital anomalies, cleft palate) at doses several times the maximum recommended human dose. In humans, data are limited but there is no clear evidence of a significant increase in major congenital malformations. First trimester exposure is not strongly associated with major defects; however, some studies suggest a possible small increase in oral clefts. Second and third trimester use may cause maternal hypotension and subsequent fetal distress (e.g., reduced uteroplacental perfusion). Use near term may theoretically inhibit labor, but nifedipine is used as a tocolytic for preterm labor. Overall, the risk is considered low; however, fetal monitoring is recommended if used in pregnancy. FDA Pregnancy Category C (prior to 2015 categorization).
No data on presence in human milk or effects on breastfed infants. Clevidipine is highly protein-bound (>99%) and rapidly metabolized, suggesting minimal excretion into milk. However, caution is advised. M/P ratio: not determined.
Nifedipine is excreted into human breast milk in small amounts. The milk-to-plasma (M/P) ratio is approximately 0.56 to 1.0 based on limited data. The estimated daily infant dose via milk is less than 5% of the maternal weight-adjusted dose, which is considered clinically insignificant. No adverse effects have been reported in breastfed infants. However, caution is advised, especially with high maternal doses or prolonged use. The American Academy of Pediatrics considers nifedipine compatible with breastfeeding.
No specific dose adjustments studied in pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered metabolism) may affect clearance, but no data. Use lowest effective dose and shortest duration. Titrate to effect with caution, as pregnant patients may have increased sensitivity to hypotensive effects.
Pregnancy may alter the pharmacokinetics of nifedipine due to increased plasma volume and altered hepatic metabolism. However, specific dosing adjustments for Adalat CC in pregnancy are not well established. In clinical practice, dosing for hypertension in pregnancy (e.g., preeclampsia) often uses immediate-release nifedipine, not extended-release. For Adalat CC, the same dosing as in non-pregnant adults (30-90 mg once daily) is typically used, but titration should be cautious to avoid maternal hypotension. No formal dose adjustment is recommended, but careful monitoring and individualized titration are advised.
CLEVIPREX (clevidipine) is an ultrashort-acting dihydropyridine calcium channel blocker for IV use in perioperative hypertension. Onset within 2-4 minutes, half-life ~1 minute. Titrate every 5-10 minutes; avoid in severe aortic stenosis, heart failure with reduced ejection fraction, and lipid disorders (formulated in lipid emulsion). Monitor for reflex tachycardia. Use aseptic technique; discard unused portion after 12 hours.
Adalat CC (nifedipine extended-release) is a dihydropyridine calcium channel blocker used primarily for hypertension. Avoid in patients with unstable angina or within 4 weeks of myocardial infarction due to reflex tachycardia risk. May cause peripheral edema, especially in higher doses; consider adding an ACE inhibitor if edema is problematic. CYP3A4 inhibitors (e.g., grapefruit juice, macrolides, azole antifungals) significantly increase nifedipine levels; avoid coadministration. Tablet shell may appear intact in stool; this is normal.
This medication is given intravenously to rapidly lower blood pressure during surgery or in hospital settings.,You will be closely monitored for heart rate and blood pressure changes during infusion.,Report any symptoms like chest pain, shortness of breath, or irregular heartbeat immediately.,Do not stop or adjust the infusion on your own; it is controlled by healthcare staff.,Inform your doctor if you have any allergies to eggs, soybeans, or lipids.
Swallow the tablet whole; do not crush or chew.,Do not consume grapefruit or grapefruit juice while taking this medication.,May cause dizziness or lightheadedness; avoid driving if affected.,Notify your doctor if you experience rapid heartbeat, swelling in the ankles or feet, or prolonged erections.,Take exactly as prescribed; do not skip doses or stop abruptly without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CLEVIPREX vs ADALAT CC, answered by our medical review team.
CLEVIPREX is a Calcium Channel Blocker that works by Cleviprex (clevidipine) is a dihydropyridine L-type calcium channel blocker with high vascular selectivity. It inhibits calcium influx into vascular smooth muscle cells, causing arterial vasodilation and reduced peripheral vascular resistance.. ADALAT CC is a Calcium Channel Blocker that works by Nifedipine, a dihydropyridine calcium channel blocker, inhibits calcium ion influx across cardiac and smooth muscle cell membranes, leading to vasodilation and decreased myocardial contractility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CLEVIPREX and ADALAT CC depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CLEVIPREX is: Initiate intravenous infusion at 1-2 mg/kg/hr, titrate by 0.5-1 mg/kg/hr every 90 minutes up to maximum 32 mg/kg/hr. Maintenance dose: 4-6 mg/kg/hr. Route: IV. Frequency: continuous infusion.. The standard adult dose of ADALAT CC is: 30 mg orally once daily; may titrate to 60 mg or 90 mg once daily based on response and tolerability.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CLEVIPREX and ADALAT CC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CLEVIPREX is classified as Category C. Cleviprex (clevidipine) is a calcium channel blocker. No adequate and well-controlled studies in pregnant women. In animal studies, no teratogenic effects were observed at clinical. ADALAT CC is classified as Category C. Adalat CC (nifedipine) is an extended-release formulation of nifedipine, a dihydropyridine calcium channel blocker. In animal studies, nifedipine has been associated with embryotox. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.